Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Janux Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 9.32M | $417M | $44.75 | Oct 18, 2024 | Indirect |
Aerovate Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 7.89M | $198M | $25.03 | Jun 17, 2024 | Indirect |
Tyra Biosciences, Inc. | Director, 10%+ Owner | Common Stock | 8.7M | $141M | $16.25 | Nov 8, 2024 | Indirect |
Cytek Biosciences, Inc. | Director, 10%+ Owner | Common Stock | 13.4M | $127M | $9.50 | Mar 15, 2022 | Indirect |
iTeos Therapeutics, Inc. | Former 10% Owner | Pre- Funded Warrants (Right to Buy) | 6.61M | $116M | $17.50 | May 12, 2024 | Indirect |
Nkarta, Inc. | Director, 10%+ Owner | Common Stock | 10.1M | $101M | $10.00 | Mar 27, 2024 | Indirect |
PepGen Inc. | Director, 10%+ Owner | Common Stock | 9.18M | $97.7M | $10.64 | Feb 9, 2024 | Indirect |
ARS Pharmaceuticals, Inc. | Director, 10%+ Owner | Common Stock | 9.96M | $97.5M | $9.79 | Mar 27, 2024 | Indirect |
Fulcrum Therapeutics, Inc. | 10%+ Owner | Common Stock | 10.2M | $79.4M | $7.76 | Sep 12, 2024 | Indirect |
4D Molecular Therapeutics, Inc. | 10%+ Owner | Common Stock | 4.56M | $74.5M | $16.33 | Dec 9, 2024 | Indirect |
89bio, Inc. | Director, 10%+ Owner | Common Stock | 13.8M | $73.7M | $5.33 | Apr 11, 2024 | Indirect |
Acrivon Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 7.91M | $67.3M | $8.50 | Apr 11, 2024 | Indirect |
Janux Therapeutics, Inc. | Director, 10%+ Owner | Pre-Funded Warrants (Right to Buy) | 1.4M | $65M | $46.50 | Mar 4, 2024 | Indirect |
Kala Pharmaceuticals, Inc. | 10%+ Owner | Common Stock | 7.04M | $47.4M | $6.74 | May 26, 2022 | Indirect |
Acumen Pharmaceuticals, Inc. | Director, 10%+ Owner | Common Stock | 13M | $45.3M | $3.47 | Jul 21, 2023 | Indirect |
Mineralys Therapeutics, Inc. | Director | Common Stock | 2.98M | $40.3M | $13.50 | Feb 12, 2024 | Indirect |
89bio, Inc. | Director, 10%+ Owner | Pre-Funded Warrants (Right to Buy) | 4.33M | $36.8M | $8.50 | Nov 14, 2024 | Indirect |
Enliven Therapeutics, Inc. | Former 10% owner | Common Stock | 2.12M | $32.1M | $15.14 | Feb 23, 2023 | Indirect |
Nkarta, Inc. | Director, 10%+ Owner | Pre- Funded Warrants (Right to Buy) | 3M | $30M | $10.00 | Mar 27, 2024 | Indirect |
Solid Biosciences Inc. | Director, 10%+ Owner | Common Stock | 4.19M | $23.2M | $5.53 | Jan 11, 2024 | Indirect |
iTeos Therapeutics, Inc. | Former 10% Owner | Common Stock | 2.55M | $21.3M | $8.37 | May 12, 2024 | Indirect |
Cidara Therapeutics, Inc. | Director | Pre-Funded Warrants (Right to Buy) | 1.29M | $19.2M | $14.91 | Nov 26, 2024 | Indirect |
Cidara Therapeutics, Inc. | Director | Common Stock | 1.09M | $16.3M | $14.91 | Nov 26, 2024 | Indirect |
Therapeutics Acquisition Corp. | Director | Common Stock | 1.1M | $13.7M | $12.45 | Jun 29, 2021 | Indirect |
LENZ Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 3.32M | $13.5M | $4.08 | Mar 21, 2024 | Indirect |
Tyra Biosciences, Inc. | Director, 10%+ Owner | Pre-Funded Warrants (Right to Buy) | 1M | $13M | $13.01 | Oct 18, 2024 | Indirect |
Eliem Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 2.87M | $11M | $3.84 | Jun 27, 2024 | Indirect |
RxSight, Inc. | 10%+ Owner | Common Stock | 214K | $10.3M | $48.00 | Aug 3, 2021 | Indirect |
Black Diamond Therapeutics, Inc. | Director | Common Stock | 3.21M | $8.77M | $2.73 | Jul 5, 2023 | Indirect |
Mineralys Therapeutics, Inc. | Director | Pre-Funded Warrants (Right to Buy) | 550K | $7.42M | $13.50 | Feb 12, 2024 | Indirect |
AN2 Therapeutics, Inc. | 10%+ Owner | Common Stock | 301K | $325K | $1.08 | Aug 9, 2024 | Indirect |
Aerovate Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 12.5K | $205K | $16.37 | Jun 5, 2024 | Indirect |
Wave Life Sciences Ltd. | Director, 10%+ Owner | Ordinary Shares | 16.1K | $40K | $2.48 | Aug 12, 2024 | Indirect |
Icosavax, Inc. | Director, 10%+ Owner | Common Stock | 0 | $0 | $15.29 | Feb 19, 2024 | Indirect |
Fulcrum Therapeutics, Inc. | 10%+ Owner | Warrant (Right to Buy) | 8.5M | Aug 21, 2024 | Indirect | ||
4D Molecular Therapeutics, Inc. | 10%+ Owner | Pre-Funded Warrants (Right to Buy) | 3.61M | Dec 9, 2024 | Indirect | ||
Bicara Therapeutics Inc. | Director, 10%+ Owner | Common Stock | 2.65M | Sep 16, 2024 | Indirect | ||
Septerna, Inc. | Director, 10%+ Owner | Common Stock | 1.47M | Oct 28, 2024 | Indirect | ||
Artiva Biotherapeutics, Inc. | Director, 10%+ Owner | Common Stock | 827K | Jul 22, 2024 | Indirect | ||
LENZ Therapeutics, Inc. | Director, 10%+ Owner | Common Stockj | 695K | Mar 21, 2024 | Indirect | ||
Boundless Bio, Inc. | 10%+ Owner | Common Stock | 296K | Apr 2, 2024 | Indirect | ||
Cidara Therapeutics, Inc. | Director | Series A Preferred Stock | 90K | Jul 19, 2024 | Indirect | ||
89bio, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 45.2K | Feb 1, 2024 | Indirect | ||
ARS Pharmaceuticals, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 40K | Jun 20, 2024 | Indirect | ||
Wave Life Sciences Ltd. | Director, 10%+ Owner | Share Option (Right to Buy) | 32.2K | Aug 12, 2024 | Indirect | ||
Vor Biopharma Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 30K | May 23, 2024 | Indirect | ||
LENZ Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 27K | Mar 21, 2024 | Indirect | ||
Acumen Pharmaceuticals, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 25K | Jun 10, 2024 | Indirect | ||
Bicara Therapeutics Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 23.7K | Sep 12, 2024 | Indirect | ||
Nkarta, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 22.5K | Jun 13, 2024 | Indirect | ||
Mineralys Therapeutics, Inc. | Director | Stock Option | 22K | May 22, 2024 | Indirect | ||
Acrivon Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 20.3K | Jun 20, 2024 | Indirect | ||
Tyra Biosciences, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 18.6K | May 29, 2024 | Indirect | ||
Werewolf Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 17.5K | May 24, 2024 | Indirect | ||
PepGen Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 13K | Jun 20, 2024 | Indirect | ||
Eliem Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 10K | Jun 26, 2024 | Indirect | ||
Solid Biosciences Inc. | Director, 10%+ Owner | Director Stock Option (Right to Buy) | 9.65K | Jun 6, 2023 | Indirect | ||
Janux Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 8.35K | Jun 26, 2024 | Indirect | ||
LENZ Therapeutics, Inc. | Director, 10%+ Owner | Warrants (Right to Buy) | 5.37K | Mar 21, 2024 | Indirect | ||
Cidara Therapeutics, Inc. | Director | Stock Option (right to buy) | 2.13K | Jul 18, 2024 | Indirect | ||
89bio, Inc. | Director, 10%+ Owner | Warrants (Right to Buy) | 0 | Apr 11, 2024 | Indirect | ||
Artiva Biotherapeutics, Inc. | Director, 10%+ Owner | Series A Preferred Stock | 0 | Jul 22, 2024 | Indirect | ||
Artiva Biotherapeutics, Inc. | Director, 10%+ Owner | Series B Preferred Stock | 0 | Jul 22, 2024 | Indirect | ||
Bicara Therapeutics Inc. | Director, 10%+ Owner | Series B Preferred Stock | 0 | Sep 16, 2024 | Indirect | ||
Bicara Therapeutics Inc. | Director, 10%+ Owner | Series C Preferred Stock | 0 | Sep 16, 2024 | Indirect | ||
Boundless Bio, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Apr 2, 2024 | Indirect | ||
Boundless Bio, Inc. | 10%+ Owner | Series C Preferred Stock | 0 | Apr 2, 2024 | Indirect | ||
DICE Therapeutics, Inc. | Former 10% owners and Director | Common Stock | 0 | $46.50 | Aug 9, 2023 | Indirect | |
DICE Therapeutics, Inc. | Former 10% owners and Director | Stock Option (Right to Buy) | 0 | Aug 9, 2023 | Indirect | ||
Forma Therapeutics Holdings, Inc. | Director, 10%+ Owner | Common Stock | 0 | $5.05 | Oct 14, 2022 | Indirect | |
Forma Therapeutics Holdings, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 0 | Oct 14, 2022 | Indirect | ||
Icosavax, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 0 | Feb 19, 2024 | Indirect | ||
Satsuma Pharmaceuticals, Inc. | Former 10% Owner | Common Stock | 0 | $0.91 | Jun 8, 2023 | Indirect | |
Satsuma Pharmaceuticals, Inc. | Former 10% Owner | Stock Option (Right to Buy) | 0 | Jun 8, 2023 | Indirect | ||
Septerna, Inc. | Director, 10%+ Owner | Series B Preferred Stock | 0 | Oct 28, 2024 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
FDMT | 4D Molecular Therapeutics, Inc. | Dec 9, 2024 | 2 | $0 | 4 | Dec 10, 2024 | 10%+ Owner |
CDTX | Cidara Therapeutics, Inc. | Nov 26, 2024 | 2 | $25M | 4 | Nov 29, 2024 | Director |
ETNB | 89bio, Inc. | Nov 14, 2024 | 1 | $27.6M | 4 | Nov 18, 2024 | Director, 10%+ Owner |
FDMT | 4D Molecular Therapeutics, Inc. | Nov 13, 2024 | 0 | $0 | 3 | Nov 25, 2024 | 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | Nov 8, 2024 | 1 | $19.8M | 4 | Nov 13, 2024 | Director, 10%+ Owner |
SEPN | Septerna, Inc. | Oct 28, 2024 | 6 | $75.1M | 4 | Oct 30, 2024 | Director, 10%+ Owner |
SEPN | Septerna, Inc. | Oct 24, 2024 | 0 | $0 | 3 | Oct 24, 2024 | Director, 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | Oct 18, 2024 | 2 | $0 | 4 | Oct 22, 2024 | Director, 10%+ Owner |
JANX | Janux Therapeutics, Inc. | Oct 18, 2024 | 1 | $53.7M | 4 | Oct 22, 2024 | Director, 10%+ Owner |
BCAX | Bicara Therapeutics Inc. | Sep 16, 2024 | 8 | $33M | 4 | Sep 18, 2024 | Director, 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 23, 2024 | 10%+ Owner |
BCAX | Bicara Therapeutics Inc. | Sep 12, 2024 | 1 | $0 | 4 | Sep 16, 2024 | Director, 10%+ Owner |
BCAX | Bicara Therapeutics Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 12, 2024 | Director, 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Aug 21, 2024 | 2 | $0 | 4 | Aug 23, 2024 | 10%+ Owner |
WVE | Wave Life Sciences Ltd. | Aug 12, 2024 | 2 | $0 | 4 | Aug 14, 2024 | Director, 10%+ Owner |
ANTX | AN2 Therapeutics, Inc. | Aug 9, 2024 | 2 | -$3.81M | 4 | Aug 13, 2024 | 10%+ Owner |
ARTV | Artiva Biotherapeutics, Inc. | Jul 22, 2024 | 12 | $105M | 4 | Jul 24, 2024 | Director, 10%+ Owner |
CDTX | Cidara Therapeutics, Inc. | Jul 18, 2024 | 3 | $100M | 4 | Jul 22, 2024 | Director |
CDTX | Cidara Therapeutics, Inc. | Jul 18, 2024 | 1 | $0 | 4/A | Jul 22, 2024 | Director |
CDTX | Cidara Therapeutics, Inc. | Jul 18, 2024 | 1 | $0 | 4 | Jul 19, 2024 | Director |
ARTV | Artiva Biotherapeutics, Inc. | Jul 18, 2024 | 0 | $0 | 3 | Jul 18, 2024 | Director, 10%+ Owner |
ELYM | Eliem Therapeutics, Inc. | Jun 27, 2024 | 5 | $50M | 4 | Jul 1, 2024 | Director, 10%+ Owner |
ELYM | Eliem Therapeutics, Inc. | Jun 26, 2024 | 1 | $0 | 4 | Jun 28, 2024 | Director, 10%+ Owner |
JANX | Janux Therapeutics, Inc. | Jun 26, 2024 | 2 | $0 | 4 | Jun 28, 2024 | Director, 10%+ Owner |
ACRV | Acrivon Therapeutics, Inc. | Jun 20, 2024 | 1 | $0 | 4 | Jun 24, 2024 | Director, 10%+ Owner |
SPRY | ARS Pharmaceuticals, Inc. | Jun 20, 2024 | 1 | $0 | 4 | Jun 24, 2024 | Director, 10%+ Owner |
PEPG | PepGen Inc. | Jun 20, 2024 | 1 | $0 | 4 | Jun 21, 2024 | Director, 10%+ Owner |
AVTE | Aerovate Therapeutics, Inc. | Jun 17, 2024 | 1 | $1.55M | 4 | Jun 20, 2024 | Director, 10%+ Owner |
NKTX | Nkarta, Inc. | Jun 13, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director, 10%+ Owner |
ABOS | Acumen Pharmaceuticals, Inc. | Jun 10, 2024 | 1 | $0 | 4 | Jun 10, 2024 | Director, 10%+ Owner |
AVTE | Aerovate Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director, 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | May 29, 2024 | 1 | $0 | 4 | May 31, 2024 | Director, 10%+ Owner |
HOWL | Werewolf Therapeutics, Inc. | May 24, 2024 | 1 | $0 | 4 | May 24, 2024 | Director, 10%+ Owner |
VOR | Vor Biopharma Inc. | May 23, 2024 | 1 | $0 | 4 | May 28, 2024 | Director, 10%+ Owner |
MLYS | Mineralys Therapeutics, Inc. | May 22, 2024 | 1 | $0 | 4 | May 28, 2024 | Director |
ITOS | iTeos Therapeutics, Inc. | May 10, 2024 | 3 | $100M | 4 | May 14, 2024 | Former 10% Owner |
CDTX | Cidara Therapeutics, Inc. | Apr 26, 2024 | 1 | $0 | 4 | Apr 30, 2024 | Director |
CDTX | Cidara Therapeutics, Inc. | Apr 24, 2024 | 0 | $0 | 3 | Apr 30, 2024 | Director |
ACRV | Acrivon Therapeutics, Inc. | Apr 11, 2024 | 1 | $30M | 4 | Apr 15, 2024 | Director, 10%+ Owner |
BOLD | Boundless Bio, Inc. | Apr 2, 2024 | 8 | $5M | 4 | Apr 4, 2024 | 10%+ Owner |
NKTX | Nkarta, Inc. | Mar 27, 2024 | 2 | $60M | 4 | Mar 29, 2024 | Director, 10%+ Owner |
BOLD | Boundless Bio, Inc. | Mar 27, 2024 | 0 | $0 | 3 | Mar 27, 2024 | 10%+ Owner |
SPRY | ARS Pharmaceuticals, Inc. | Mar 25, 2024 | 3 | $13.3M | 4 | Mar 27, 2024 | Director, 10%+ Owner |
LENZ | LENZ Therapeutics, Inc. | Mar 21, 2024 | 9 | $15M | 4 | Mar 25, 2024 | Director, 10%+ Owner |
LENZ | LENZ Therapeutics, Inc. | Mar 21, 2024 | 0 | $0 | 3 | Mar 25, 2024 | Director |
ETNB | 89bio, Inc. | Mar 4, 2024 | 1 | $20.7M | 4 | Mar 6, 2024 | Director, 10%+ Owner |
JANX | Janux Therapeutics, Inc. | Mar 4, 2024 | 1 | $65M | 4 | Mar 6, 2024 | Director, 10%+ Owner |
ICVX | Icosavax, Inc. | Feb 19, 2024 | 5 | $0 | 4 | Feb 20, 2024 | Director, 10%+ Owner |
MLYS | Mineralys Therapeutics, Inc. | Feb 12, 2024 | 2 | $30M | 4 | Feb 14, 2024 | Director |
PEPG | PepGen Inc. | Feb 9, 2024 | 1 | $27.2M | 4 | Feb 13, 2024 | Director, 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | Feb 6, 2024 | 2 | $61.4M | 4 | Feb 8, 2024 | Director, 10%+ Owner |
SLDB | Solid Biosciences Inc. | Jan 11, 2024 | 1 | $5M | 4 | Jan 12, 2024 | Director, 10%+ Owner |
WVE | Wave Life Sciences Ltd. | Dec 11, 2023 | 1 | $5M | 4/A | Jan 17, 2024 | Director, 10%+ Owner |
WVE | Wave Life Sciences Ltd. | Dec 11, 2023 | 1 | $5M | 4 | Dec 13, 2023 | Director, 10%+ Owner |
ETNB | 89bio, Inc. | Dec 11, 2023 | 1 | $10M | 4 | Dec 13, 2023 | Director, 10%+ Owner |
SPRY | ARS Pharmaceuticals, Inc. | Sep 21, 2023 | 2 | $8.18M | 4 | Sep 25, 2023 | Director |
SPRY | ARS Pharmaceuticals, Inc. | Aug 29, 2023 | 1 | $23.3M | 4 | Aug 31, 2023 | Director |
ANTX | AN2 Therapeutics, Inc. | Aug 18, 2023 | 1 | $16M | 4 | Aug 22, 2023 | 10%+ Owner |
DICE | DICE Therapeutics, Inc. | Aug 9, 2023 | 3 | $0 | 4 | Aug 9, 2023 | Former 10% owners and Director |
WVE | Wave Life Sciences Ltd. | Aug 7, 2023 | 1 | $0 | 4 | Aug 9, 2023 | Director, 10%+ Owner |
ABOS | Acumen Pharmaceuticals, Inc. | Jul 21, 2023 | 1 | $40M | 4 | Jul 25, 2023 | Director, 10%+ Owner |
JANX | Janux Therapeutics, Inc. | Jul 19, 2023 | 2 | $12.4M | 4 | Jul 21, 2023 | Director, 10%+ Owner |
BDTX | Black Diamond Therapeutics, Inc. | Jul 5, 2023 | 1 | $4.68M | 4 | Jul 7, 2023 | Director |
SPRY | ARS Pharmaceuticals, Inc. | Jun 27, 2023 | 1 | $0 | 4 | Jun 28, 2023 | Director |
HOWL | Werewolf Therapeutics, Inc. | Jun 21, 2023 | 1 | $0 | 4 | Jun 23, 2023 | Director, 10%+ Owner |
JANX | Janux Therapeutics, Inc. | Jun 14, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director, 10%+ Owner |
STSA | Satsuma Pharmaceuticals, Inc. | Jun 8, 2023 | 4 | $0 | 4 | Jun 12, 2023 | Former 10% Owner |
NKTX | Nkarta, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director, 10%+ Owner |
ABOS | Acumen Pharmaceuticals, Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 13, 2023 | Director, 10%+ Owner |
AVTE | Aerovate Therapeutics, Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
SLDB | Solid Biosciences Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
ICVX | Icosavax, Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | May 31, 2023 | 1 | $0 | 4 | Jun 2, 2023 | Director, 10%+ Owner |
VOR | Vor Biopharma Inc. | May 26, 2023 | 1 | $0 | 4 | Jun 2, 2023 | Director, 10%+ Owner |
ELYM | Eliem Therapeutics, Inc. | May 18, 2023 | 1 | $0 | 4 | May 22, 2023 | Director, 10%+ Owner |
DICE | DICE Therapeutics, Inc. | Mar 28, 2023 | 3 | $14.8M | 4 | Mar 30, 2023 | Director, 10%+ Owner |
ETNB | 89bio, Inc. | Mar 24, 2023 | 1 | $40M | 4 | Mar 30, 2023 | Director, 10%+ Owner |
DICE | DICE Therapeutics, Inc. | Mar 23, 2023 | 3 | $13.5M | 4 | Mar 27, 2023 | Director, 10%+ Owner |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Feb 27, 2023 | Former 10% owner |
MLYS | Mineralys Therapeutics, Inc. | Feb 14, 2023 | 6 | $20M | 4 | Feb 16, 2023 | Director |
ETNB | 89bio, Inc. | Feb 9, 2023 | 4 | $7.5M | 4 | Apr 15, 2024 | Director, 10%+ Owner |
MLYS | Mineralys Therapeutics, Inc. | Feb 9, 2023 | 1 | $0 | 4 | Feb 13, 2023 | Director, 10%+ Owner |
MLYS | Mineralys Therapeutics, Inc. | Feb 9, 2023 | 0 | $0 | 3 | Feb 9, 2023 | Director, 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Jan 20, 2023 | 1 | $25M | 4 | Jan 24, 2023 | 10%+ Owner |
HOWL | Werewolf Therapeutics, Inc. | Jan 6, 2023 | 1 | $4.1M | 4 | Jan 10, 2023 | Director, 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Jan 4, 2023 | 2 | $1.31M | 4 | Jan 6, 2023 | 10%+ Owner |
ELVN | IMARA Inc. | Jan 3, 2023 | 1 | $2.52M | 4 | Jan 5, 2023 | 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Dec 27, 2022 | 1 | $24.5K | 4 | Dec 29, 2022 | 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Dec 19, 2022 | 1 | $583K | 4 | Dec 21, 2022 | 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Dec 14, 2022 | 3 | $13.1M | 4 | Dec 16, 2022 | 10%+ Owner |
SLDB | Solid Biosciences Inc. | Dec 13, 2022 | 1 | $0 | 4 | Dec 15, 2022 | Director, 10%+ Owner |
VOR | Vor Biopharma Inc. | Dec 9, 2022 | 1 | $50M | 4 | Dec 9, 2022 | Director, 10%+ Owner |
ELVN | IMARA Inc. | Dec 8, 2022 | 2 | $116K | 4 | Dec 12, 2022 | 10%+ Owner |
SLDB | Solid Biosciences Inc. | Dec 2, 2022 | 3 | $15.2M | 4 | Dec 5, 2022 | Director, 10%+ Owner |
ACRV | Acrivon Therapeutics, Inc. | Nov 17, 2022 | 5 | $42.4M | 4 | Nov 21, 2022 | Director, 10%+ Owner |
ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2022 | 1 | $0 | 4 | Nov 16, 2022 | Director, 10%+ Owner |
ACRV | Acrivon Therapeutics, Inc. | Nov 9, 2022 | 0 | $0 | 3 | Nov 9, 2022 | Director, 10%+ Owner |
SPRY | ARS Pharmaceuticals, Inc. | Nov 8, 2022 | 2 | $0 | 4 | Nov 10, 2022 | Director |
SPRY | ARS Pharmaceuticals, Inc. | Nov 8, 2022 | 0 | $0 | 3 | Nov 10, 2022 | Director |
ELVN | IMARA Inc. | Oct 20, 2022 | 3 | $337K | 4 | Oct 24, 2022 | 10%+ Owner |
ETNB | 89bio, Inc. | Oct 18, 2022 | 1 | $8.97M | 4 | Oct 20, 2022 | Director, 10%+ Owner |
ELVN | IMARA Inc. | Oct 17, 2022 | 3 | $1.86M | 4 | Oct 19, 2022 | 10%+ Owner |
DICE | DICE Therapeutics, Inc. | Oct 17, 2022 | 1 | $59.9M | 4 | Oct 19, 2022 | Director, 10%+ Owner |
ELVN | IMARA Inc. | Oct 17, 2022 | 0 | $0 | 3 | Oct 19, 2022 | 10%+ Owner |
FMTX | Forma Therapeutics Holdings, Inc. | Oct 14, 2022 | 6 | $0 | 4 | Oct 14, 2022 | Director, 10%+ Owner |
FULC | Fulcrum Therapeutics, Inc. | Aug 16, 2022 | 0 | $0 | 3 | Aug 26, 2022 | 10%+ Owner |
WVE | Wave Life Sciences Ltd. | Aug 15, 2022 | 1 | $0 | 4 | Aug 17, 2022 | Director, 10%+ Owner |
ANTX | AN2 Therapeutics, Inc. | Aug 3, 2022 | 2 | $14.3K | 4 | Aug 5, 2022 | 10%+ Owner |
ANTX | AN2 Therapeutics, Inc. | Jul 26, 2022 | 2 | $181K | 4 | Jul 28, 2022 | 10%+ Owner |
ETNB | 89bio, Inc. | Jul 1, 2022 | 2 | $10M | 4 | Jul 6, 2022 | Director, 10%+ Owner |
ANTX | AN2 Therapeutics, Inc. | Jun 21, 2022 | 1 | $2.41K | 4 | Jun 23, 2022 | 10%+ Owner |
AVTE | Aerovate Therapeutics, Inc. | Jun 21, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Director, 10%+ Owner |
WVE | Wave Life Sciences Ltd. | Jun 16, 2022 | 2 | $35.6M | 4 | Jun 21, 2022 | Director, 10%+ Owner |
ABOS | Acumen Pharmaceuticals, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 21, 2022 | Director, 10%+ Owner |
VOR | Vor Biopharma Inc. | Jun 14, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director, 10%+ Owner |
JANX | Janux Therapeutics, Inc. | Jun 14, 2022 | 1 | $0 | 4 | Jun 16, 2022 | Director, 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | Jun 13, 2022 | 1 | $0 | 4 | Jun 15, 2022 | Director, 10%+ Owner |
ANTX | AN2 Therapeutics, Inc. | Jun 13, 2022 | 2 | $647K | 4 | Jun 15, 2022 | 10%+ Owner |
ICVX | Icosavax, Inc. | Jun 10, 2022 | 2 | $0 | 4 | Jun 14, 2022 | Director, 10%+ Owner |
ITOS | iTeos Therapeutics, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
NKTX | Nkarta, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
FTMX | Forma Therapeutics Holdings, Inc. | Jun 8, 2022 | 2 | $0 | 4 | Jun 9, 2022 | Director, 10%+ Owner |
SLDB | Solid Biosciences Inc. | Jun 7, 2022 | 1 | $0 | 4 | Jun 9, 2022 | Director, 10%+ Owner |
DICE | DICE Therapeutics, Inc. | Jun 7, 2022 | 1 | $0 | 4 | Jun 8, 2022 | Director, 10%+ Owner |
STSA | Satsuma Pharmaceuticals, Inc. | Jun 3, 2022 | 1 | $0 | 4 | Jun 7, 2022 | Director, 10%+ Owner |
HOWL | Werewolf Therapeutics, Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 3, 2022 | Director, 10%+ Owner |
KALA | Kala Pharmaceuticals, Inc. | May 26, 2022 | 1 | -$366K | 4 | May 26, 2022 | 10%+ Owner |
KALA | Kala Pharmaceuticals, Inc. | May 23, 2022 | 3 | -$1.49M | 4 | May 25, 2022 | 10%+ Owner |
ELYM | Eliem Therapeutics, Inc. | May 19, 2022 | 1 | $0 | 4 | Jun 1, 2022 | Director, 10%+ Owner |
ETNB | 89bio, Inc. | May 16, 2022 | 1 | $0 | 4 | Jun 2, 2022 | Director, 10%+ Owner |
PEPG | PepGen Inc. | May 10, 2022 | 10 | $38.8M | 4 | May 12, 2022 | Director, 10%+ Owner |
PEPG | PepGen Inc. | May 6, 2022 | 1 | $0 | 4 | May 10, 2022 | Director, 10%+ Owner |
PEPG | PepGen Inc. | May 5, 2022 | 0 | $0 | 3/A | May 12, 2022 | Director, 10%+ Owner |
ANTX | AN2 Therapeutics, Inc. | Mar 29, 2022 | 6 | $25M | 4 | Mar 31, 2022 | 10%+ Owner |
ICVX | Icosavax, Inc. | Mar 28, 2022 | 2 | $837K | 4 | Mar 30, 2022 | Director, 10%+ Owner |
ANTX | AN2 Therapeutics, Inc. | Mar 24, 2022 | 0 | $0 | 3 | Mar 24, 2022 | 10%+ Owner |
CTKB | Cytek Biosciences, Inc. | Mar 14, 2022 | 2 | $7.19M | 4 | Mar 16, 2022 | Director, 10%+ Owner |
CTKB | Cytek Biosciences, Inc. | Mar 9, 2022 | 3 | $8.16M | 4 | Mar 11, 2022 | Director |
CTKB | Cytek Biosciences, Inc. | Mar 4, 2022 | 3 | $8.25M | 4 | Mar 8, 2022 | Director |
CTKB | Cytek Biosciences, Inc. | Feb 28, 2022 | 3 | $5.72M | 4 | Mar 2, 2022 | Director |
CTKB | Cytek Biosciences, Inc. | Feb 23, 2022 | 3 | $5.56M | 4 | Feb 25, 2022 | Director |
CTKB | Cytek Biosciences, Inc. | Feb 17, 2022 | 3 | $7.7M | 4 | Feb 22, 2022 | Director |
NKTX | Nkarta, Inc. | Feb 14, 2022 | 1 | $33M | 4 | Apr 28, 2022 | Director, 10%+ Owner |
CTKB | Cytek Biosciences, Inc. | Feb 14, 2022 | 3 | $7.43M | 4 | Feb 16, 2022 | Director |
DICE | DICE Therapeutics, Inc. | Sep 17, 2021 | 8 | $23.8M | 4 | Sep 20, 2021 | Director, 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | Sep 17, 2021 | 9 | $20M | 4 | Sep 17, 2021 | Director, 10%+ Owner |
DICE | DICE Therapeutics, Inc. | Sep 14, 2021 | 0 | $0 | 3 | Sep 14, 2021 | Director, 10%+ Owner |
TYRA | Tyra Biosciences, Inc. | Sep 14, 2021 | 0 | $0 | 3 | Sep 14, 2021 | Director, 10%+ Owner |
WVE | Wave Life Sciences Ltd. | Aug 16, 2021 | 1 | $0 | 4 | Aug 18, 2021 | Director, 10%+ Owner |
ELYM | Eliem Therapeutics, Inc. | Aug 12, 2021 | 14 | $40M | 4 | Aug 16, 2021 | Director, 10%+ Owner |
ELYM | Eliem Therapeutics, Inc. | Aug 9, 2021 | 1 | $0 | 4 | Aug 11, 2021 | Director, 10%+ Owner |
ELYM | Eliem Therapeutics, Inc. | Aug 9, 2021 | 0 | $0 | 3 | Aug 9, 2021 | Director, 10%+ Owner |
RXST | RxSight, Inc. | Aug 3, 2021 | 0 | $0 | 3 | Aug 13, 2021 | 10%+ Owner |
ICVX | Icosavax, Inc. | Aug 2, 2021 | 6 | $40M | 4 | Aug 4, 2021 | Director, 10%+ Owner |
ICVX | Icosavax, Inc. | Jul 28, 2021 | 0 | $0 | 3 | Jul 28, 2021 | Director, 10%+ Owner |
CTKB | Cytek Biosciences, Inc. | Jul 27, 2021 | 8 | $50.2M | 4 | Jul 29, 2021 | Director |
CTKB | Cytek BioSciences, Inc. | Jul 22, 2021 | 0 | $0 | 3 | Jul 22, 2021 | Director |
ABOS | Acumen Pharmaceuticals, Inc. | Jul 6, 2021 | 8 | $30M | 4 | Jul 8, 2021 | Director, 10%+ Owner |
AVTE | Aerovate Therapeutics, Inc. | Jul 2, 2021 | 8 | $39M | 4 | Jul 6, 2021 | Director, 10%+ Owner |
ABOS | Acumen Pharmaceuticals, Inc. | Jun 30, 2021 | 0 | $0 | 3 | Jun 30, 2021 | Director, 10%+ Owner |
PNT | Therapeutics Acquisition Corp. | Jun 29, 2021 | 1 | $2.09M | 4 | Jun 30, 2021 | Director |
AVTE | Aerovate Therapeutics, Inc. | Jun 29, 2021 | 0 | $0 | 3 | Jun 29, 2021 | Director, 10%+ Owner |
PNT | Therapeutics Acquisition Corp. | Jun 23, 2021 | 0 | $0 | 3 | Jun 24, 2021 | Director |
JANX | Janux Therapeutics, Inc. | Jun 15, 2021 | 10 | $50M | 4 | Jun 16, 2021 | Director, 10%+ Owner |
HOWL | Werewolf Therapeutics, Inc. | Jun 14, 2021 | 3 | $4.13M | 4 | Jun 16, 2021 | Director, 10%+ Owner |
JANX | Janux Therapeutics, Inc. | Jun 10, 2021 | 0 | $0 | 3 | Jun 10, 2021 | Director, 10%+ Owner |
ETNB | 89bio, Inc. | Jun 2, 2021 | 1 | $416K | 4 | Jun 4, 2021 | Director, 10%+ Owner |
ETNB | 89bio, Inc. | May 26, 2021 | 3 | $3.86M | 4 | May 28, 2021 | Director, 10%+ Owner |